These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23022285)

  • 1. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.
    Beck GR; Khazai NB; Bouloux GF; Camalier CE; Lin Y; Garneys LM; Siqueira J; Peng L; Pasquel F; Umpierrez D; Smiley D; Umpierrez GE
    Transl Res; 2013 Mar; 161(3):145-55. PubMed ID: 23022285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.
    Benvenuti S; Cellai I; Luciani P; Deledda C; Baglioni S; Giuliani C; Saccardi R; Mazzanti B; Dal Pozzo S; Mannucci E; Peri A; Serio M
    J Endocrinol Invest; 2007 Oct; 30(9):RC26-30. PubMed ID: 17993761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal consequences of thiazolidinedione therapy.
    Grey A
    Osteoporos Int; 2008 Feb; 19(2):129-37. PubMed ID: 17901911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Do thiazolidinediones harm skeletal integrity?].
    Takeuchi Y
    Clin Calcium; 2008 May; 18(5):650-5. PubMed ID: 18445884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
    Lecka-Czernik B
    Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myricetin 3-
    Karadeniz F; Oh JH; Jo HJ; Seo Y; Kong CS
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
    Bilik D; McEwen LN; Brown MB; Pomeroy NE; Kim C; Asao K; Crosson JC; Duru OK; Ferrara A; Hsiao VC; Karter AJ; Lee PG; Marrero DG; Selby JV; Subramanian U; Herman WH
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4560-5. PubMed ID: 20631021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine.
    Xia WF; Jung JU; Shun C; Xiong S; Xiong L; Shi XM; Mei L; Xiong WC
    J Bone Miner Res; 2013 Oct; 28(10):2122-35. PubMed ID: 23649480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro.
    Okazaki R; Toriumi M; Fukumoto S; Miyamoto M; Fujita T; Tanaka K; Takeuchi Y
    Endocrinology; 1999 Nov; 140(11):5060-5. PubMed ID: 10537132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis.
    Gustafson B; Eliasson B; Smith U
    Diabetologia; 2010 Mar; 53(3):536-40. PubMed ID: 19943155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes.
    Schwartz AV; Sellmeyer DE
    Expert Opin Drug Saf; 2008 Jan; 7(1):69-78. PubMed ID: 18171315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convergence of TGFβ and BMP signaling in regulating human bone marrow stromal cell differentiation.
    Elsafadi M; Shinwari T; Al-Malki S; Manikandan M; Mahmood A; Aldahmash A; Alfayez M; Kassem M; Alajez NM
    Sci Rep; 2019 Mar; 9(1):4977. PubMed ID: 30899078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
    J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinedione use and bone loss in older diabetic adults.
    Schwartz AV; Sellmeyer DE; Vittinghoff E; Palermo L; Lecka-Czernik B; Feingold KR; Strotmeyer ES; Resnick HE; Carbone L; Beamer BA; Park SW; Lane NE; Harris TB; Cummings SR
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3349-54. PubMed ID: 16608888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Skeletal effects of thiazolidinediones].
    Okazaki R
    Nihon Rinsho; 2000 Feb; 58(2):456-60. PubMed ID: 10707576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
    Sorocéanu MA; Miao D; Bai XY; Su H; Goltzman D; Karaplis AC
    J Endocrinol; 2004 Oct; 183(1):203-16. PubMed ID: 15525588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factors 1 and 2 inhibit adipogenesis of human bone marrow stromal cells in 3D collagen gels.
    Le Blanc S; Simann M; Jakob F; Schütze N; Schilling T
    Exp Cell Res; 2015 Nov; 338(2):136-48. PubMed ID: 26384550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
    Grey A
    Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
    Loke YK; Singh S; Furberg CD
    CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone.
    Bruedigam C; Eijken M; Koedam M; van de Peppel J; Drabek K; Chiba H; van Leeuwen JP
    Stem Cells; 2010 May; 28(5):916-27. PubMed ID: 20213769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.